|
Patent landscape, scope, and claims: |
Patent 5,770,599 (US) scope and claims: how broad is the quinazoline derivative estate and what compounds/processes/compositions fall inside?
Executive summary: US 5,770,599 claims (1) a structurally defined class of substituted quinazoline derivatives (Formula I) with broad substituent allowances for halogen/trifluoromethyl (R2), alkoxy (R3), and amino-alkoxy/heterocycle-alkoxy side chains (R1), (2) enumerated “specific embodiments” with defined aryl anilino, methoxy, and alkoxy substitutions, (3) multiple chemical synthesis routes (via quinazoline electrophiles, anilines, and late-stage etherification/amino-functionalization logic), and (4) pharmaceutical compositions and an anti-proliferative method-of-use. The claim architecture is dense: Markush-style genus coverage for analogs plus narrower dependent claims that lock key substructures (examples include particular halo/anilino patterns and R1 side chains).
What patents protect quinazoline derivatives like those in US 5,770,599? (Scope of Formula I, Markush breadth, and captured analogs)
US 5,770,599 is a “core chemical” patent built around Formula I quinazoline derivatives with defined constraints on three substitution handles: (R2)n, R3, and R1. The claims are written to capture both (a) an analog space around a defined quinazoline scaffold and (b) concrete species via dependent claims and explicit examples.
Claim 1 (genus): what structural rules must a product satisfy to infringe?
Claim 1 recites a quinazoline derivative of Formula I where:
- n is 1, 2 or 3
- Each R2 is independently halogeno or trifluoromethyl
- R3 is (1–4C)alkoxy
- R1 is a substituted alkoxy “linker” that bears amino/heterocycle functionality, selected from:
- di-(1–4C)alkylamino-(2–4C)alkoxy
- pyrrolidin-1-yl-(2–4C)alkoxy
- piperidino-(2–4C)alkoxy
- morpholino-(2–4C)alkoxy
- piperazin-1-yl-(2–4C)alkoxy
- 4-(1–4C)alkylpiperazin-1-yl-(2–4C)alkoxy
- imidazol-1-yl-(2–4C)alkoxy
- di-(1–4C)alkoxy-(2–4C)alkylamino-(2–4C)alkoxy
- thiamorpholino-(2–4C)alkoxy
- 1-oxothiamorpholino-(2–4C)alkoxy
- 1,1-dioxothiamorpholino-(2–4C)alkoxy
- CH2 methylene constraint: “wherein any of the above-mentioned R1 substituents comprising a CH2 group which is not attached to a N or O atom optionally bears a hydroxy substituent.”
- Or pharmaceutically acceptable salt.
Practical breadth:
- The largest exclusion-risk for an infringer is not the quinazoline core; it is whether their molecule fits the R1 class (amino-alkoxy with specific linker lengths and heteroatom identity) and the R2/R3 alkoxy allowances.
- The “optional hydroxy on a non-N/O attached CH2” is a secondary feature that can increase capture of hydroxylated analogs without excluding non-hydroxylated analogs.
What do claims 2–6 do to narrow the genus?
Claims 2–6 retain Formula I but tighten substituent specificity:
- Claim 2: R2 limited to halogeno or trifluoromethyl (same as claim 1 in substance) and limits R1 to a subset of listed amino/heterocycle alkoxy types (removing some variations present in claim 1, like thiamorpholino variants and certain “di-alkoxy-alkylamino” permutations depending on the exact recitation).
- Claims 3–6: specify exact R2 patterns (e.g., combinations like 3’-fluoro-4’-chloro; 2’,4’-difluoro; etc.), set R3 = methoxy, and specify R1 choices down to defined side-chain identities and (in some cases) positional/length details.
Where do the patent’s “species anchors” live? Claims 7–14
Claims 7–14 list discrete compounds of Formula I with:
- “4-(3′-chloro-4′-fluoroanilino)-7-methoxy” and specific 6-(alkoxy) substituents (pyrrolidine, morpholine, diethylamino, dimethylamino, imidazole, piperidinyl, etc.), or
- “4-(3′,4′-difluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)” and related enumerations.
These claims function as high-confidence coverage points for exact drug-like embodiments and as “fallback” positions if a defendant argues the broader genus is avoided.
How are salts treated? Claims 1–15 and species salts
All relevant product claims end with “or a pharmaceutically-acceptable salt thereof.” Claim 15 specifically claims:
- the hydrochloride salt of the enumerated compound in claim 14.
This matters for enforcement because it covers marketed salt forms if the free base is not used (or vice versa).
Claim 19: a compact “selected group” claim
Claim 19 recites a group comprising:
- 4-(3′-chloro-4′-fluoroanilino)-6-(2-dimethylaminoethoxy)-7-methoxyquinazoline
- 4-(2′,4′-difluoroanilino)-6-(3-dimethylaminopropoxy)-7-methoxyquinazoline
- 4-(2′,4′-difluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline
- 4-(3′-chloro-4′-fluoroanilino)-6-(2-imidazol-1-ylethoxy)-7-methoxyquinazoline
- 4-(3′-chloro-4′-fluoroanilino)-6-(3-imidazol-1-ylpropoxy)-7-methoxyquinazoline
and salts.
This “group consisting of” format is narrower than the genus but provides a clean list for litigation claim charting.
Which R1 side chains and linker patterns are explicitly covered in US 5,770,599? (R1 feature map and design-around risk)
R1 covered chemotypes (as written)
US 5,770,599 claim language covers amino-alkoxy and heterocycle-alkoxy substituents with:
- heteroatoms: N-containing amino/heterocycles; O-containing morpholino; sulfur-oxygen thiamorpholino derivatives
- flexible alkyl spacer sizes: “(2–4C)alkoxy” and “(2–4C)alkyl” subcomponents
- a “CH2 not attached to N or O” optionally bearing OH
R1 feature sensitivity for design-around
The clearest non-infringement pathway is structural mismatch on at least one of the following:
- R1 not being “(2–4C)alkoxy” tethered to the heterocycle/amino group as defined
- replacement of the amino/heterocycle moiety with a non-listed ring type (even if similar polarity)
- changing the spacer length outside 2–4 carbon range
- changing the quinazoline substitution pattern at the positions corresponding to the claim’s anilino linkage and methoxy (R3) when dependent claims are asserted
The genus claim 1 is broad enough that many “close” analogs can still fall inside unless they change one of these defining elements.
What formulations are protected by US 5,770,599? (Composition claim scope and implied dosage coverage)
Claim 17: pharmaceutical composition
Claim 17 is a standard “composition comprising” clause:
- “a quinazoline derivative of Formula I, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable diluent or carrier.”
What it does and does not cover
- It covers any formulation that uses a claimed compound, but it does not claim specific dosage forms, controlled release, excipients, or stability/solvate architectures.
- It is strongest in asserting infringement against products whose active is inside the claimed chemical scope.
What method-of-use claims exist in US 5,770,599 and how broad is the “anti-proliferative effect” language?
Claim 18: anti-proliferative effect in warm-blooded animals
Claim 18 covers:
- “a method for producing an anti-proliferative effect in a warm-blooded animal”
- comprising administering an effective amount of a compound of claims 1–15 or salt.
Claim breadth
- The claim does not specify disease indications by name. It covers the biological effect broadly.
- It does not limit dose, route, or regimen in the excerpt you provided.
- If asserted, the focus becomes: does the administered active fall within claims 1–15, and does the administration aim to produce the claimed anti-proliferative effect.
What processes for preparing the compounds are protected by US 5,770,599? (Synthesis routes captured by claim 16)
Claim 16: multi-step process coverage
Claim 16 recites a process comprising reaction logic among:
- a quinazoline of Formula II with Z as a displaceable group, and an aniline of Formula III
- then, depending on the R1 type, additional transformations:
- (b) for R1 that is amino-substituted alkoxy: alkylation of a quinazoline derivative where R1 is hydroxy
- (c) for R1 amino-substituted alkoxy: reaction of a hydroxy-alkoxy compound (or reactive derivative) with an appropriate amine
- (d) for R1 hydroxy-amino-alkoxy: reaction of a compound containing a 2,3-epoxypropoxy or 3,4-epoxybutoxy group with an appropriate amine
- salt formation by conventional acid reaction if needed.
Enforcement implication
- Process claims can be leveraged against manufacturing if evidence ties production steps to this route and uses starting materials/reagents within the claim’s described transformations.
- The presence of multiple branches (b), (c), (d) increases coverage across different process-development strategies that use common intermediate logic: hydroxy/epoxide to amino-alkoxy formation.
How strong is the patent estate for specific quinazoline species inside US 5,770,599? (Species vs genus enforceability)
Enforceability hierarchy inside the claim set
- Claim 19: “group consisting of” specific compounds creates clean infringement anchors.
- Claims 7–15: enumerated structures plus specific salt (hydrochloride) also support direct claim charts.
- Claims 3–6: restrict to particular halogen patterns and R1 methoxy embodiments, narrowing disputes about what qualifies as “close.”
- Claim 1: broadest genus but potentially more litigated due to greater room for alleged non-inclusion in substituted analogs and due to typical validity scrutiny against prior art genus coverage.
How does US 5,770,599 compare with typical quinazoline patent breadth? (Genus + dependent species architecture)
Compared with patents that only claim a single lead compound, US 5,770,599 is structured to cover:
- a scaffold-defined analog space (Formula I genus)
- fixed substitution patterns (claims 3–6)
- multiple explicitly named embodiments (claims 7–14, 19)
- product form factors only at a high level (claim 17)
- a broad biological method-of-use (claim 18)
- multiple synthetic routes for generating R1 amino/heterocycle alkoxy side chains (claim 16)
This is a common “defensive” architecture aimed at both compound-centric enforcement and manufacturing/process leverage.
Timing and exclusivity: when does US 5,770,599 lose exclusivity? (Patent term framework)
No filing, priority, expiration, or maintenance-fee history is provided in your input, so a precise exclusivity/timeline cannot be produced from the claim text alone.
Orange Book status, FDA approval, and Paragraph IV risk for US 5,770,599: what can be concluded from the claims alone?
No drug name, NDA/ANDA/BLA reference listed drug, or Orange Book entry data is provided in your input.
Commercial and competitive exposure: what products would likely trigger infringement risk from US 5,770,599?
Based on claim scope alone, infringement risk concentrates on:
- marketed or clinical quinazoline actives that match the Formula I pattern, especially:
- “anilino” quinazolines with 7-methoxy (R3 = methoxy) and halogenated R2 patterns like 3′-chloro/4′-fluoro or 2′,4′-difluoro
- R1 substituents that are amino-alkoxy or heterocycle-alkoxy with linker lengths 2–4 carbon
- salt forms (including specific hydrochloride in claim 15)
- manufacturing processes that build R1 via hydroxy/epoxide intermediates and then attach amines (claim 16)
Key Takeaways
- Claim 1 creates a broad genus around substituted quinazoline derivatives with flexible R2 and R3 options and a defined set of amino/heterocycle-alkoxy R1 substituents plus an optional OH on specific non-N/O-attached methylene carbons.
- Claims 3–6 and 7–14 narrow the substituent pattern to specific halogen combinations and specify R3 as methoxy, making them high-value fallback coverage for enforcement.
- Claims 7–14, 15, and 19 provide explicit species and a specific hydrochloride salt, supporting straightforward infringement claim charts.
- Claim 16 captures multiple synthetic routes using quinazoline electrophiles with displaceable groups plus late-stage installation of amino-alkoxy R1 via alkylation, amine substitution on hydroxy-alkoxy/derivatives, or epoxide opening.
- Claim 17 covers any pharmaceutical formulation using a claimed compound with standard diluent/carrier language.
- Claim 18 covers broadly the administration of the claimed compound to produce an anti-proliferative effect in warm-blooded animals.
FAQs
-
Does US 5,770,599 cover salts beyond hydrochloride?
Yes. The claims use “pharmaceutically acceptable salt thereof” in multiple places, with hydrochloride explicitly claimed for the compound in claim 14 (claim 15).
-
Is R3 limited to methoxy?
No for the genus claim 1: R3 is (1–4C)alkoxy. Some narrower dependent claims specifically set R3 = methoxy.
-
Do the claims require the R1 side chain to include an amino or a heterocycle?
Yes. Claim 1 limits R1 to specified amino-substituted alkoxy and heterocycle-alkoxy substituents (including piperazine, morpholine, imidazole, thiamorpholine variants, and related options).
-
Are process claims tied to a specific reaction order?
Claim 16 is route-based rather than time-based: it requires reaction of an electrophilic quinazoline (Formula II with a displaceable Z) with an aniline (Formula III) and then branch steps to install the R1 functionality based on whether R1 starts as hydroxy, is converted via hydroxy-alkoxy intermediates, or derived from epoxides.
-
Does the method-of-use claim identify a particular cancer type or indication?
Not in the excerpt provided. Claim 18 is defined by an anti-proliferative effect in warm-blooded animals, without naming specific diseases.
References (APA)
- United States Patent 5,770,599, “Quinazoline derivatives and processes for their preparation,” claims as provided in user input.
More… ↓
⤷ Start Trial
|
